Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02324439 · ClinicalTrials.gov registry record · Phase 1

Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission

A Phase 1 study, sponsored by Southern Illinois University.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target

NCT02324439 is a Phase 1 study that has completed, run by Southern Illinois University. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02324439, a Phase 1 study, has completed, sponsored by Southern Illinois University.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target

Study Summary

This is a phase 0/phase I feasibility trial to test the hypothesis that flaxseed supplementation is an effective maintenance therapy for patients with ovarian cancer who are in clinical remission following platinum-based regimens. The investigators further hypothesize levels of estrogen metabolites and prostaglandin E2 in this patient population will correlate with recurrence of disease, extent of tumor burden, invasion and metastasis.

Interventions

  • DRUG Omega Nutrition cold-milled flaxseeds

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2015-03
Est. Completion 2021-03
Phase Phase 1

Sponsor

Southern Illinois University

21 total trials

What the Registry Record Tells You About NCT02324439

The ClinicalTrials.gov registry entry for NCT02324439 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern Illinois University, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Omega Nutrition cold-milled flaxseeds is the first listed.

NCT02324439 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02324439 about?

NCT02324439 is a clinical study titled "Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission". This is a phase 0/phase I feasibility trial to test the hypothesis that flaxseed supplementation is an effective maintenance therapy for patients with ovarian cancer who are in clinical remission following platinum-based regimens. The investigators further hypothesize levels of estrogen metabolites ...

What is the current status of trial NCT02324439?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-03. Estimated completion is 2021-03.

What interventions are being tested in trial NCT02324439?

The interventions under investigation include: Omega Nutrition cold-milled flaxseeds (DRUG).

Who is sponsoring clinical trial NCT02324439?

This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.